Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulsed iNO in PH-COPD and PH-IPF
NCT02267655Phase 1Completed
- Sponsor
- Bellerophon Therapeutics
- Start
- May 2015
- Primary completion
- Jun 2017
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nitric oxide in pulmonary hypertension (PH) (4 arms), sponsored by Bellerophon Therapeutics. Primary endpoint: Change from baseline in lobar blood volume at total lung capacity (TLC) at 4 weeks. Started May 2015; status: completed.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT02267655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267655.